Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents

View ORCID ProfileJessica A. Breznik, View ORCID ProfileAli Zhang, View ORCID ProfileAngela Huynh, View ORCID ProfileMatthew S. Miller, View ORCID ProfileIshac Nazy, View ORCID ProfileDawn M. E. Bowdish, View ORCID ProfileAndrew P. Costa, for the COVID-in-LTC Study Group
doi: https://doi.org/10.1101/2021.08.17.21262152
Jessica A. Breznik
1McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada
2Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
3Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica A. Breznik
Ali Zhang
1McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada
2Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
4Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ali Zhang
Angela Huynh
3Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angela Huynh
Matthew S. Miller
1McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada
2Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
4Department of Biochemistry & Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew S. Miller
Ishac Nazy
3Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
5McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ishac Nazy
Dawn M. E. Bowdish
1McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada
2Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada
3Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
6Firestone Institute of Respiratory Health, St Joseph’s Healthcare, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dawn M. E. Bowdish
  • For correspondence: bowdish@mcmaster.ca
Andrew P. Costa
3Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
7Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada
8Centre for Integrated Care, St. Joseph’s Health System, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew P. Costa
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Nursing home residents often fail to mount robust responses to vaccinations and recent reports of breakthrough infections, particularly from variants of concern, raise questions about whether vaccination regimens elicit a sufficient humoral immune response or if booster doses are warranted. We examined SARS-CoV-2 antibody levels and neutralizing capacity in nursing home residents 3-5 months after 2 doses of mRNA-1273 or BNT163b2 vaccination as per recommended schedules.

Nursing home residents were recruited from eight long-term care homes in Ontario, Canada, between March and July 2021. Antibody levels and neutralization capacity from a previously published convalescent cohort were used as a comparator. Serum SARS-CoV-2 IgA/G/M against spike (S) protein and its receptor-binding domain (RBD) were measured by validated ELISA, with assay cut-off at the mean and 3 standard deviations of a pre-COVID-19 population from the same geographic region. Antibody neutralization was measured against the wild-type strain of SARS-CoV-2 and the beta variant of concern (B.1.351).

No neutralizing antibodies were detected in ∼20% of residents to the wild-type virus (30/155; 19%) or beta variant (27/134; 20%). Residents that received BNT163b2 had a ∼4-fold reduction in neutralization to the wild-type strain, and a ∼2-fold reduction in neutralization to the beta variant relative to those who received mRNA-1273.

Current mRNA SARS-CoV-2 vaccine regimens may not have equivalent efficacy in nursing home residents. Our findings imply that differences in the humoral immune response may contribute to breakthrough infections, and suggest that consideration of the type of vaccine administered to older adults will have a positive impact on the generation of protective immunity.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada awarded to Costa and Bowdish. Bowdish is the Canada Research Chair in Aging & Immunity. Costa is the Schlegel Chair in Clinical Epidemiology and Aging. Funding support for this work was provided by grants from the Ontario Research Fund, COVID-19 Rapid Research Fund, and by the Canadian COVID-19 Immunity Task Force awarded to Nazy. Miller is supported, in part, by an Ontario Early Researcher Award.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All protocols were approved by the Hamilton Integrated Research Ethics Board (HiREB), and informed consent was obtained.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest Disclosures: None reported.

  • Additional Information: Members of the COVID-in-LTC Study Group include: Jonathan L. Bramson, PhD; Eric D. Brown, PhD; Kevin Brown, PhD; David C. Bulir, MD, PhD; Judah A. Denburg, MD; George A. Heckman, MD, MSc; Michael P. Hillmer, PhD; John P. Hirdes, PhD; Aaron Jones, PhD; Mark Loeb, MD, MSc; Janet E. McElhaney, MD; Ishac Nazy, PhD; Nathan M. Stall, MD; Parminder Raina, PhD; Marek Smieja, MD, PhD; Kevin J. Stinson, PhD; Ahmad Von Schlegell; Arthur Sweetman, PhD; Chris Verschoor, PhD; Gerry Wright, PhD.

  • Funding: This work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada awarded to Costa and Bowdish. Bowdish is the Canada Research Chair in Aging & Immunity. Costa is the Schlegel Chair in Clinical Epidemiology and Aging. Funding support for this work was provided by grants from the Ontario Research Fund, COVID-19 Rapid Research Fund, and by the Canadian COVID-19 Immunity Task Force awarded to Nazy. Miller is supported, in part, by an Ontario Early Researcher Award.

  • Correction of word errors that we're corrected in submission to peer-reviewed journal.

Data Availability

Data are not available without prior approval from the Hamilton Integrated Research Ethics Board (HiREB).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 19, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents
Jessica A. Breznik, Ali Zhang, Angela Huynh, Matthew S. Miller, Ishac Nazy, Dawn M. E. Bowdish, Andrew P. Costa, for the COVID-in-LTC Study Group
medRxiv 2021.08.17.21262152; doi: https://doi.org/10.1101/2021.08.17.21262152
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents
Jessica A. Breznik, Ali Zhang, Angela Huynh, Matthew S. Miller, Ishac Nazy, Dawn M. E. Bowdish, Andrew P. Costa, for the COVID-in-LTC Study Group
medRxiv 2021.08.17.21262152; doi: https://doi.org/10.1101/2021.08.17.21262152

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (658)
  • Epidemiology (10796)
  • Forensic Medicine (8)
  • Gastroenterology (589)
  • Genetic and Genomic Medicine (2946)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1927)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12515)
  • Intensive Care and Critical Care Medicine (688)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2798)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1463)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2639)
  • Public and Global Health (5363)
  • Radiology and Imaging (1011)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)